Literature DB >> 17405800

Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema.

Mark C Gillies1, F M Amirul Islam, Meidong Zhu, Jorgen Larsson, Tien Y Wong.   

Abstract

AIM: The efficacy and safety of repeated injections of intravitreal triamcinolone (IVTA) for diabetic macular oedema is unclear, with results of previous reports conflicting.
METHODS: This is a prospective, observational case series of 27 eyes receiving IVTA for diabetic macular oedema. LogMAR visual acuity (VA) and central macular thickness (CMT) were measured at baseline and in 3 to 6 monthly intervals for up to 24 months, then correlated with the number of IVTA injections given.
RESULTS: One IVTA injection was required in 6 (18%) eyes, 2 in 8 (24%) eyes, 3 in 13 (39%) eyes and 4-5 in 6 (18%) eyes. VA improved in all patients, but neither the final improvement in VA nor the absolute improvement in CMT from baseline to 24 months correlated with the number of injections received (p = 0.44 and 0.84, respectively). Cataract surgery was more frequent in eyes receiving more injections (p = 0.01).
CONCLUSIONS: This study suggests that repeated injections of IVTA continue to be as effective as the first over a 2-year period. The probability of cataract surgery increases with an increasing number of injections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17405800      PMCID: PMC2000996          DOI: 10.1136/bjo.2006.113167

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  8 in total

1.  Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.

Authors:  Mark C Gillies; Florian K P Sutter; Judy M Simpson; Jorgen Larsson; Haipha Ali; Meidong Zhu
Journal:  Ophthalmology       Date:  2006-07-07       Impact factor: 12.079

2.  Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone.

Authors:  Jörgen Larsson; Meidong Zhu; Florian Sutter; Mark C Gillies
Journal:  Am J Ophthalmol       Date:  2005-05       Impact factor: 5.258

3.  The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-02       Impact factor: 5.258

4.  Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.

Authors:  Florian K P Sutter; Judy M Simpson; Mark C Gillies
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

5.  Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema.

Authors:  C K M Chan; S Mohamed; M P Shanmugam; C-W Tsang; T Y Y Lai; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

Review 6.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.

Authors:  C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

7.  Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Ulrich H Spandau; Bernd A Kamppeter; Urs Vossmerbaeumer; Björn Harder; Gangolf Sauder
Journal:  Ophthalmology       Date:  2006-03-13       Impact factor: 12.079

8.  Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial.

Authors:  Mark C Gillies; Judy M Simpson; Frank A Billson; Wei Luo; Philip Penfold; William Chua; Paul Mitchell; Meidong Zhu; Alex B L Hunyor
Journal:  Arch Ophthalmol       Date:  2004-03
  8 in total
  7 in total

1.  Efficacy of Ozurdex implant in recalcitrant diabetic macular edema--a single-center experience.

Authors:  Pooja Bansal; Vishali Gupta; Amod Gupta; Mangat Ram Dogra; Jagat Ram
Journal:  Int Ophthalmol       Date:  2015-08-02       Impact factor: 2.031

2.  Macular cysts, holes and cavitations : 2006 Jules Gonin lecture of the Retina Research Foundation.

Authors:  A Gaudric
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-30       Impact factor: 3.117

3.  Current treatments in diabetic macular oedema: systematic review and meta-analysis.

Authors:  John Alexander Ford; Noemi Lois; Pamela Royle; Christine Clar; Deepson Shyangdan; Norman Waugh
Journal:  BMJ Open       Date:  2013-03-01       Impact factor: 2.692

4.  Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema.

Authors:  Roderick O'Day; Daniel Barthelmes; Meidong Zhu; Tien Yin Wong; Ian L McAllister; Jennifer J Arnold; Mark C Gillies
Journal:  Clin Ophthalmol       Date:  2013-08-02

Review 5.  Intravitreal steroids for the treatment of retinal diseases.

Authors:  Valentina Sarao; Daniele Veritti; Francesco Boscia; Paolo Lanzetta
Journal:  ScientificWorldJournal       Date:  2014-01-08

6.  Effects of triamcinolone acetonide on human trabecular meshwork cells in vitro.

Authors:  Ashish Sharma; A Jayaprakash Patil; Navin Gupta; M F Estrago-Franco; Saffar Mansoor; Vincent Raymond; M Cristina Kenney; Baruch D Kuppermann
Journal:  Indian J Ophthalmol       Date:  2014-04       Impact factor: 1.848

Review 7.  Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials.

Authors:  Nigel A Calcutt; Mark E Cooper; Tim S Kern; Ann Marie Schmidt
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.